FTSE MIB
33.831,93 +85,27 (+0,25%) Dow Jones
37.903,29 +87,37 (+0,23%) Nasdaq
15.605,48 -52,34 (-0,33%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
79,26 +0,26 (+0,33%) Bitcoin EUR
54.812,12 +723,27 (+1,34%)
INCY Nov 2024 55.000 put
| Chiusura precedente | 4,9100 |
| Aperto | 4,9100 |
| Denaro | 0,0000 |
| Lettera | 0,0000 |
| Prezzo d'esercizio | 55,00 |
| Scadenza | 2024-11-15 |
| Min-Max giorno | 4,9100 - 4,9100 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 418 |
GlobeNewswireGlobal CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic
GlobeNewswireKnight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for pemigatinib to ANVISA, the Brazilian health regulatory agency, under the rare diseases approval pathway, for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor recepto
